Core Insights - The China Business Conditions Index (BCI) for June recorded at 49.3, a slight decline from May's 50.3, indicating a contraction in business conditions [1] Group 1: Business Indices - The BCI is composed of four sub-indices, with two declining, one rising, and one remaining unchanged this month [1] - The Business Sales Expectations Index decreased from 57.3 in the previous month to 54.6 this month [1] - The Business Profit Expectations Index also saw a decline, dropping from 46.6 last month to 43.8 this month [1] - The Business Financing Environment Index remained stable at 49.1 [1] - The Business Inventory Expectations Index increased slightly from 48.3 last month to 49.8 this month [1] Group 2: Cost and Price Expectations - The Labor Cost Expectations Index experienced a minor decline from 60.7 last month to 59.9 this month [1] - The Total Cost Expectations Index also saw a small decrease, from 62.7 last month to 59.2 this month [1] - The Consumer Goods Price Expectations Index fell from 45.2 last month to 43.8 this month [1] - The Intermediate Goods Price Expectations Index increased slightly from 33.6 last month to 36.6 this month [1]

智通财经6月27日电，港股收盘，理想汽车发布公告更新2025年第二季度交付量指引。受到地方补贴退 坡、新车密集上市、"以价换量"导致的市场观望情绪加剧等影响，20万以上中高端车市场大盘增长失 速，豪华品牌销量同比大幅下滑。理想汽车预计2025年第二季度交付量为10.8万辆。李想表示纯电SUV 理想i8上市前完成销售体系升级，支持纯电产品销售，预计随着7月和9月两款纯电SUV完成上市，品牌 销量将进一步回升，冲击销量新高。 理想汽车：销售组织调整升级 更新Q2交付目标 ...

Pro版，售价 27.99 万元。 而最顶配的MAX 版本也是不负众望， 售价直接突破了20万的大关，来到了32.99 万元。 兄弟们的，大家中午好。 咱们等了 好几个月的 小米YU7终于正式发布了，废话不多说，直接上价格。 小米YU7跟之前的SU 7一样，也是拥有3个版本。 标准版，售价25.35 万元。 具体的配置和价格对比图如下。 | YU7 | | ¥253,500起 | YU7 Pro | ¥279,900起 | YU7 Max ×329900起 | | --- | --- | --- | --- | --- | --- | | 835 km | 5.88 Xiaomi HAD | | 770 km | 4.27 s Xiaomi HAD | 760 km 3.23s Xiaomi HAD | | 续航里程(CLTC) | 百公里加速 小米端到端辅助驾驶 | | 续航里程(CLTC) 百公里加速 小米端到端辅助驾驶 | | 续航里程(CLTC) 百公里加速 小米端到端辅助驾驶 | | 800V 平台 235kW 单电机后驱 | | | 800V 平台 365kW 双电机四驱 | | 800V 平台 ...

抱歉，原计划标题是" YU7上市后，你觉得这车成了吗？"，但看到昨晚3分钟20万订单，1小时28.9万的战绩后，这个原定标题就显得很傻…… 这次我们只找到两位小米销售能聊一下即时的销售情况，而且这两位也都工作到凌晨，其中一位5点才睡觉。 更详细的内容，会体现在小米YU7抢拍文章中。本篇横评，就看看一线兄弟在半梦半醒的状态下，最直接的感受是什么。 注：本文图片来源于团队其他小伙伴的实拍，并非参与话题的销售门店，实在没时间拍。 之前有担心过YU7上市后会不会影响SU7的订单，现在的好消息就是SU7开放了转单。 雷老板还是非常有魄力的，更好的消息是愿意等SU7的客户，订单要提速 了。现在比较头疼的是后续YU7的交付进度了。 小米汽车 南方地区 写完这段内容已经5点了，如果今天就发的话，大家看到的时候我应该还在睡觉。 先说YU7的定价，起售价在我们销售的预料之中，但是中配Pro版，也就是27.99万那一款比预计中要低个1万块钱左右。嗯，70%的客户觉得非常划得来，剩下的 20%是期待25万以内，还有10%是看热闹，下个订单就退了。 YU7有一部分的现车大概率是8月份开始交付，包括首批车主也是8月份提车。 订单情况不是 ...

日本5月大型零售商销售同比 0.6%，前值 1.5%。 ...

日本5月零售销售环比 -0.2%，预期 0.3%，前值 0.5%。 ...

Core Viewpoint - Japan's retail sales in May increased by 2.2% year-on-year, which is below the expected growth of 2.5% and a decrease from the previous value of 3.3% [1] Group 1 - The year-on-year growth rate of Japan's retail sales for May was reported at 2.2% [1] - The expected growth rate for May was 2.5%, indicating a shortfall in performance [1] - The previous month's growth rate was 3.3%, showing a decline in retail sales growth [1]

Group 1 - Japan's retail sales in May showed a seasonally adjusted month-on-month decline of 0.2%, which was below the expected increase of 0.3% [1] - The previous month's retail sales growth was revised from 0.50% to 0.70% [1]

Group 1 - Japan's retail sales in May increased by 2.2% year-on-year, which is below the expected growth of 2.7% [1] - The previous value of retail sales growth was revised from 3.30% to 3.50% [1]

Core Viewpoint - Guizhou Bailing Pharmaceutical Group Co., Ltd. received an inquiry letter from the Shenzhen Stock Exchange regarding its 2024 annual report, highlighting issues related to the audit opinion and internal control deficiencies [1][2]. Financial Performance - The company reported a revenue of 3.825 billion yuan in 2024, a decrease of 10.26% year-on-year. However, the net profit attributable to shareholders was 33.62 million yuan, an increase from a net loss of 82.44 million yuan in the previous year, marking an 81.33% improvement [25][26]. - The operating cash flow was 9.02 million yuan, a significant decrease of 92.83% compared to the previous year [25]. Audit Opinion - The annual auditor, Tianjian Accounting Firm, issued a qualified opinion on the 2024 financial report due to insufficient evidence regarding the realizable net value of certain raw materials and the recognition of sales expenses from the previous year [1][2][10]. - The audit highlighted two main issues: disputes over shareholding ratios with minority shareholders and ongoing investigations by the China Securities Regulatory Commission [1][2]. Inventory Valuation - The company assessed the realizable net value of its inventory, specifically a type of traditional Chinese medicine, based on a 10-year shelf life, concluding that there were no impairment signs [3][5]. - The inventory included 883.84 tons of raw materials, with a calculated impairment provision of approximately 58.38 million yuan [4][5]. Internal Control Issues - The company identified 288 million yuan in sales expenses that were not recorded in previous years, attributed to insufficient accruals and communication issues with sales offices and agents [5][6]. - Following a negative internal control audit opinion in 2023, the company implemented corrective measures, resulting in a new audit report for 2024 that indicated the elimination of previous deficiencies [16][18]. Legal Disputes - The company is involved in legal disputes regarding the shareholding of its subsidiary, He Ren Tang Pharmaceutical Co., Ltd., with ongoing litigation concerning the ownership of 40% of the shares [6][7]. - The company has taken legal action to contest a court ruling that awarded shares to a minority shareholder, and the case is currently under review [6][7]. Customer and Supplier Concentration - The top five customers accounted for 39.13% of total sales, while the top five suppliers represented 46.05% of total purchases, indicating a high concentration risk [25][26].